Peptides DB
Research-centric peptide and protocol reference hub

AICAR (Acadesine) record · updated 17h ago

Metabolic & appetiteMuscle & body compGrade B · human evidenceResearch use only
All 4 studiesJump to the evidenceCompare
What is AICAR (Acadesine) used for?

AICAR (Acadesine) is a small-molecule AMPK activator studied for metabolic, endurance, and cardioprotective effects. It mimics AMP to shift cells toward energy-producing pathways.

How it works: AMPK activator

Primarily researched for · Metabolic & appetite

Development stage

where AICAR (Acadesine) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 5 registered trials. It describes the research record, not a recommendation.

Identity
NameAICAR (Acadesine)
Full name—
Sequence—
ClassMetabolic
Research levelLimited Research
Discovered byCurated master list · 2026
Pharmacology
MechanismAMPK activator
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
Metabolic & appetite: Healing 1.0, Muscle 2.0, Metabolic 5.0, Neuro 1.0, Sleep 0.0, Immune 2.0, Skin 0.0Healing & recovery — 1.0 / 5Muscle & body comp — 2.0 / 5Metabolic & appetite — 5.0 / 5Neuro & mood — 1.0 / 5Inflammation & immune — 2.0 / 5HealingMuscleMetabolicNeuroSleepImmuneSkin1.02.05.01.00.02.00.0
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 27, 2026. How this works →
Research stats
Total studies4
Human / animal / cellular1 / 2 / 1
Highest trial phasePreclinical
Years covered2026
Latest study8d ago
Publication history
20262026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

4 rowsOpen in the library →
StudyTypeYearSummary depth
Pharmacological inhibition of TRPM4 channel stabilizes atherosclerotic plaque via inhibiting AMPK-Beclin1-mediated autophagy.
FindingNot reported in abstract.
Animal2026Full text read0.70
Apolipoprotein C3 exacerbates vascular calcification by promoting ferroptosis via the TLR2/AMPK pathway in vascular smooth muscle cells.
FindingNot reported in abstract.
Animal2026Full text read0.70
Roles of RRM2 and RRM2B in pyrimidine stress responses and differentiation of acute myeloid leukemia cells.
FindingNot reported in abstract.
In vitro2026Full text read0.70
Plasma proteomics stratification identifies phospholamban R14del carriers at risk for disease progression.
FindingNot reported in abstract.
Human2026Full text read0.80

Articles mentioning AICAR (Acadesine)